NEW DELHI (AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drug maker Novartis AG for its lifesaving cancer treatment Gleevec. A victory for the company, aid groups warned, could open the door to patenting dozens of other generic medicines made by India's $20 billion drug industry and sold to needy nations at far lower costs than those charged by Western drug manufacturers.
No comments:
Post a Comment